Asthma is one of the most common chronic diseases of childhood. Fortunately, most children with asthma have a mild or moderate form of the disease [1], and symptom control can be achieved by ensuring adequate provision of care and continuously addressing the basics in asthma management through shared decision-making with patients and their families. However, asthma remains difficult to treat for a small proportion of children who may be symptomatic despite aggressive maintenance therapy and after management issues like adherence to treatment have been addressed [2, 3]. The expression “a small proportion” is anecdotal, since estimating the “true” prevalence of severe asthma in childhood has proved challenging. Epidemiological research on this topic is hampered by the heterogeneity in criteria used to define and classify paediatric severe asthma, as well as the scarcity of validated monitoring and outcome-assessment tools [2, 3]. Moreover, even with the adoption of a more standardised and internationally acknowledged definition, an accurate estimate of severe asthma prevalence should be based on very large population cohort studies including information on therapy not only by questionnaires but also from pharmacy-dispensed prescriptions.
The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS clinical research collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers / Grigg, J; Rusconi, F; Grigg, J; Rusconi, F; van Aalderen, W; Rutjes, Nwp; Carlsen, Kcl; Coleman, C; Chalmers, Jd; Cunningham, S; Fernandes, Rm; Fleming, Lj; Frankemölle, B; Gappa, M; Karadag, B; Liu, Nm; Midulla, F; Pijnenburg, MARIA WILHELMINA HELENA. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 1399-3003. - 52:4(2018). [10.1183/13993003.01665-2018]
The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS clinical research collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers
Midulla F;
2018
Abstract
Asthma is one of the most common chronic diseases of childhood. Fortunately, most children with asthma have a mild or moderate form of the disease [1], and symptom control can be achieved by ensuring adequate provision of care and continuously addressing the basics in asthma management through shared decision-making with patients and their families. However, asthma remains difficult to treat for a small proportion of children who may be symptomatic despite aggressive maintenance therapy and after management issues like adherence to treatment have been addressed [2, 3]. The expression “a small proportion” is anecdotal, since estimating the “true” prevalence of severe asthma in childhood has proved challenging. Epidemiological research on this topic is hampered by the heterogeneity in criteria used to define and classify paediatric severe asthma, as well as the scarcity of validated monitoring and outcome-assessment tools [2, 3]. Moreover, even with the adoption of a more standardised and internationally acknowledged definition, an accurate estimate of severe asthma prevalence should be based on very large population cohort studies including information on therapy not only by questionnaires but also from pharmacy-dispensed prescriptions.File | Dimensione | Formato | |
---|---|---|---|
Rusconi_SPACE_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
134.55 kB
Formato
Adobe PDF
|
134.55 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.